Ulcerative colitis: COMMAND Study (Risankizumab)

by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing

Ulcerative colitis: COMMAND Study (Risankizumab) This study focuses on the drug risankizumab. It examines various phases, including a 52-week maintenance phase and open-label extensions, to assess safety and efficacy in patients who have previously responded to...

Ulcerative colitis: ABTECT Maintenance Study

by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing

Ulcerative colitis: ABTECT Maintenance Study This study tests the long-term safety and efficacy of the drug ABX464, taken once daily as maintenance therapy. It is aimed at patients who have not responded to other treatments—both conventional and advanced...

ABTECT-1 Study on Ulcerative Colitis – Study Partners

by Pauline Lauterbach | Jan 16, 2026 | For study partners

ABTECT-1 Study on Ulcerative Colitis ABTECT-1 – Evaluation of Treatment with ABX464 for Ulcerative Colitis – 1 ClinicalTrials.gov ID: NCT05507203Sponsor: Abivax S.A. (Information provided by Abivax S.A. (responsible party)) Official Title A Randomized, Double-Blind,...

ABTECT-1 Study on Ulcerative Colitis

by Pauline Lauterbach | Jan 16, 2026 | Completed, For participants

ABTECT-1 Study on Ulcerative Colitis A recent study tested ABX464, a new drug for people with moderate to severe ulcerative colitis who have not responded to standard treatments. Participants received either ABX464 or a placebo to determine if the drug can alleviate...

Ulcerative colitis: MIRACLE study – Study partners

by Pauline Lauterbach | Jan 16, 2026 | Active, Searching, For study partners

Ulcerative colitis: MIRACLE study – Study partners Efficacy of top-down therapy with mirikizumab compared to standard therapy with azathioprine in patients with newly diagnosed moderate to severe ulcerative colitis (MIRACLE) ClinicalTrials.gov ID: NCT07235904Sponsor:...